COMP <GO>
GH vs ABBV // 10Y YIELD & FRED MACRO BETA
Guardant Health Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: GH 4
— ABBV 10
▲ 10Y YIELD & FRED MACRO BETA LEADER: ABBV
LAST: $178.80 (-3.51%) • MKT CAP: $24.87B
macro-sensitivity
0.87
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.50% | 70.20% | -5.70 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -17.40% | 29.00% | -46.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.94% | 3.47% | -4.41 | ABBV | /fcf-yield <GO> |
| Operating Margin | -44.50% | 24.60% | -69.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -42.40% | 6.90% | -49.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 32.90% | 8.60% | +24.30 | GH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.44 | 5.33 | +0.11 | GH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.40% | -0.90 | GH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 72.8 | -15.53 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.87 | 1.15 | -0.28 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.0x | 113.1x | -94.10 | GH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.87B | $513.86B | -$488.99B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GH REV | ABBV REV | GH GROSS % | ABBV GROSS % | GH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $982.0M | $61.16B | 64.5% | 70.2% | -$233.1M | $17.82B |
| FY 2024 | $739.0M | $56.33B | 60.8% | 70.0% | -$274.9M | $17.83B |
| FY 2023 | $563.9M | $54.32B | 44.0% | 44.0% | -$350.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GH // BETA 0.87
ABBV // BETA 1.15